

























































Imaging primarymitral regurgitation: the
whole is better than the sum of its parts
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This editorial refers to ‘The evolving role of cardiac mag-
netic resonance in primary mitral regurgitation: ready for
prime time?’ by B. Liu et al. doi:10.1093/ehjci/jey147.
There is the ‘What we want’ and the ‘What we need’ in the goals of
imaging the mitral valve (MV) in primary mitral regurgitation (MR).1
The delineation of the underlying morphological abnormalities of the
MV, the degree of MR, and the haemodynamic consequences of MR
are among the ‘What we want’ category. These important questions
can be answered in most instances by 2D and 3D transthoracic and
transoesophageal echocardiography (TTE and TOE, respectively).
Liu et al.2 provide an update into the potential role for cardiac mag-
netic resonance (CMR) imaging in the evaluation of primary MR. Not
surprisingly, this excellent review confirms that 2D and 3D echo are
sufficient to address the key ‘What we want’ issues in most circum-
stances, but with well-known limitations in specific circumstances. In
these specific circumstances, CMR provides an avenue to reliably as-
sess the lesion, especially the severity of MR. The measurement of
regurgitant volume (RVol) and fraction (RF) is the most notable con-
tribution of CMR in this regard. Both, right ventricle (RV) and RF can
be measured by 2D echo and more recently by 3D colour flow
Doppler.3 But, the former is cumbersome, prone to errors, and not
routinely done in practice, while the latter is promising as a tool but is
not widely available and needs further studies to establish accuracy
and feasibility. This is where CMR offers a clear incremental value and
fills an important gap between guidelines or recommendations and
real-world practice in the assessment of MR severity. We should all
be thinking about RVol and RF measured by CMR in challenging cases
rather that leaning on unreliable PISA effective regurgitatnt orifice
area (EROA) or PISA-derived RV/RF by 2D or 3D echo only.4 There
is no shame for echocardiographers to seek CMR in challenging cir-
cumstances, and likewise for CMR enthusiasts to acknowledge that
echocardiography works in most circumstances. Both have limita-
tions in the real-world and there are such things as poor quality echo-
cardiography and CMR. We have more data on the quality of
echocardiography in general because much more echocardiograms
are done compared with CMR, especially for MR. But, there are
poorly done CMRs also, we just do not know the real-world rates of
these are. So, the ‘What we want’ category often descends into argu-
ment about which among the modalities is superior. But, this is not
relevant to the real-world practice. When high quality TTE and TOE,
and equally competent physicians are available, these modalities form
the cornerstone for the evaluation of primary MR. This applies even
when excellent CMR services are available, because RF is not neces-
sary in every case of primary MR. When the echo resources are lim-
ited in quality and competency, CMR may be done more often in the
evaluation of MR. It is interesting to note however, that most centres
with excellent CMR also tend to have at least good if not excellent
echo resources. It is harder to find a centre where CMR is excellent
when echo services are poor, although these do exist. This co-
dependency of the quality of the twomodalities is fortuitous but critic-
al for good patient care, which is ultimately the goal of any institution.
The ‘What we need’ in primary MR, however does not necessarily
stop with accurate, reliable, and reproducible quantification of the se-
verity of MR. In fact, the triggers for intervention in primary severe
MR are presence of symptoms or evidence of left ventricular (LV) en-
largement or reduced LV systolic function (which is currently meas-
ured by ejection fraction, EF).5 Measurement of LV size and EF is
where 2D echocardiography can be unreliable especially for serial
measurements during follow-up. Another instance when accuracy of
these LV indices become critical for decision-making is when there is
discrepancy between these and the degree of MR. There is consensus
that CMR is more accurate and reproducible than 2D echocardiog-
raphy for measurements of LV volumes and EF. Although the guide-
lines recommend end-systolic linear dimension as an index of LV size,
this is based on the fact that there is very little data on outcomes
based on LV volumes. But, as described in the article by Liu et al.,2
there is an evolving literature on predictive value of LV volumes
measured by CMR in primary MR, and these data may yet refine the
guidelines in the future. But, unlike LV volumes the argument that ac-
curate and reproducible measurement of left ventricular ejection
fraction (LVEF) by CMR is necessary is less clear because 2D echo
with contrast or 3D echocardiography can measure one-time EF
with similar, if not the same degree of accuracy as CMR. However,
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for detection of progressive increase in LV size or decrease in EF
(which is a class IIA indication for intervention in the guidelines),
CMR is more reliable. But, LVEF >60% in primary severe MR does
not necessarily indicate normal LV contractility, which is a key meas-
ure of myocardial function in volume overload situation. Thus, myo-
cardial strain measurement especially global longitudinal strain (GLS)
is emerging as a marker of myocardial contractility. The use of GLS as
a marker of myocardial dysfunction and trigger for intervention in pri-
mary MR needs further investigation and outcomes data.6 The CMR
correlate of this index may be its unique ability to detect and quantify
the myocardial scar/fibrosis burden in primary MR, and it is possible
that this may predate abnormalities in GLS. Myocardial scar may also
have value over and above prediction of occult LV dysfunction in that,
the presence of regional myocardial scar possibly identifies high-risk
substrate for malignant ventricular arrhythmias and sudden cardiac
death.7 There is also work being done to use intra-ventricular flow pat-
terns to detect abnormal LV wall shear, which may even precede
abnormalities in myocardial strain or development of fibrosis and scar.
Both echocardiography and CMR can be used to map intra-ventricular
flow signature. Finally, exercise response of the LV and Doppler
haemodynamics in primary MR is a key option in evaluation of patients
with discrepant findings compared with symptoms.8 This option may
be necessary even after CMR measurements if there is continued dis-
crepancy. Echocardiography is uniquely suited for this purpose.
In summary, there is much for us to learn about the timing of inter-
vention in primary MR. The past arguments of which imaging modal-
ity is better is not only short-sighted but also irrelevant to current
surgical and the rapidly evolving transcatheter technologies for the
treatment of MR.9 The ‘What we want’ needs to be combined with
the ‘What we need’ to truly provide a clinically useful imaging strategy
to take care of the patient with primary MR. From the many modal-
ities and indices we want one thing, that is to be able to integrate all
the information to intervene in timely and successful fashion: E
Pluribus Unum.
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